- Home
- J&J Innovative Medicine
J&J Innovative Medicine
Biomedical scientist Robert Langer receives the 2023 Dr. Paul Janssen Award for Biomedical Research
Each year, Johnson & Johnson honors a scientist currently working in academia, industry or a scientific institute who has made a significant contribution toward the improvement of public health.
Johnson & Johnson named a 2024 Fortune World’s Most Admired Company
The company makes the list for the 22nd year in a row, thanks to its dedication to innovation, social responsibility and more.
Is this the end of one-size-fits-all treatments for depression?
For World Mental Health Day, learn how Johnson & Johnson is working to bring personalized psychiatry to the 7 in 10 people with depression whose treatments aren’t getting the job done.
3 ways Johnson & Johnson is helping make healthcare more sustainable
Climate change is intertwined with just about every industry worldwide, including healthcare. For Earth Day, here’s a look at how Johnson & Johnson is taking action to help support a healthy planet.
Harnessing the human genome is the future of healthcare—and Johnson & Johnson is helping lead the way
The company’s partnership with the largest human genome sequencing project in the world will increase scientists’ understanding of genetic diseases and help create new interventions. Here, a look at the breakthroughs that have guided the understanding of the power of DNA.
What it’s like when your baby has a rare blood disorder
A condition called fetal and neonatal alloimmune thrombocytopenia (FNAIT) can be deadly in newborns. That’s why Johnson & Johnson is passionate about developing a treatment for the disorder.
What you need to know about Johnson & Johnson’s 2023 third-quarter earnings
Check out this infographic breakdown of the company’s third-quarter 2023 performance, with key highlights from its Innovative Medicine and MedTech businesses.
Behind the relentless pursuit of multiple myeloma cures
Johnson & Johnson has been dedicated to developing innovative treatments for blood cancers for nearly 20 years. Scientist Kodandaram “Ram” Pillarisetti is at the forefront of the company’s commitment to working toward its goal of one day eliminating the disease.
What you need to know about Johnson & Johnson’s 2023 second-quarter earnings
Check out this infographic breakdown of the company’s second-quarter 2023 performance, with key highlights from its Pharmaceutical, MedTech and Consumer Health businesses.